VelaLabs, located in Vienna, is proud to introduce the successful implementation of high resolution mass spectrometry for its use during characterization of impurities and degradants. Although the demand for such analysis in a science hot spot like Vienna is huge, Vela´s services are not regionally restricted and available for pharma and biotech clients worldwide.
Recently, an in-house research project was completed, where orthogonal methods for characterization of different excipients were established. The main focus here was on Polysorbate 80 quantitation (HPLC-ELSD), characterization of its heterogeneity and degradants (HPLC-Q-TOF-MS) and analysis of fatty acid profiles (GC-MS). Depending on the molecules investigated, additional methods can also be employed e.g. capillary electrophoresis and SEC-MALLS for proteins.
Markus Roucka, Chief Business Development & Marketing Officer at VelaLabs, says, “Our vision is delivering analytical excellence and out-of-the-box-thinking for our customers from support during early stage method development to validated batch release methods. As structural characterization of impurities and degradantsis already included in our method development strategy, the risk of unwelcome surprises during product analysis can be drastically reduced”.
For further support in the analysis of pharmaceuticals or research projects please contact our business developer Markus Roucka (m.roucka@vela-labs.at).
About VelaLabs
VelaLabs is a world-wide acting, GMP-certified and GCLP-compliant contract service provider focussed on protein characterization e.g. biosimilars, biopharmaceuticals and quality control of various drugs. Since 2018 VelaLabs is also listed on the FDA´s Drug Establishments Current Registration Site (ID #: 3006414285). A highly motivated team with a broad expertise in analytical development is the basis of Vela´s approach that allows offering tailor-made solutions for a wide range of unique customers.
Recently, an in-house research project was completed, where orthogonal methods for characterization of different excipients were established. The main focus here was on Polysorbate 80 quantitation (HPLC-ELSD), characterization of its heterogeneity and degradants (HPLC-Q-TOF-MS) and analysis of fatty acid profiles (GC-MS). Depending on the molecules investigated, additional methods can also be employed e.g. capillary electrophoresis and SEC-MALLS for proteins.
Markus Roucka, Chief Business Development & Marketing Officer at VelaLabs, says, “Our vision is delivering analytical excellence and out-of-the-box-thinking for our customers from support during early stage method development to validated batch release methods. As structural characterization of impurities and degradantsis already included in our method development strategy, the risk of unwelcome surprises during product analysis can be drastically reduced”.
For further support in the analysis of pharmaceuticals or research projects please contact our business developer Markus Roucka (m.roucka@vela-labs.at).
About VelaLabs
VelaLabs is a world-wide acting, GMP-certified and GCLP-compliant contract service provider focussed on protein characterization e.g. biosimilars, biopharmaceuticals and quality control of various drugs. Since 2018 VelaLabs is also listed on the FDA´s Drug Establishments Current Registration Site (ID #: 3006414285). A highly motivated team with a broad expertise in analytical development is the basis of Vela´s approach that allows offering tailor-made solutions for a wide range of unique customers.
